Drug · DIN 02320045
METOJECT
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since July 17, 2019; first marketed January 26, 2009.
- Drug Identification Number (DIN)
- 02320045
- Company (DIN owner)
- Medexus Pharmaceuticals Inc.Bolton, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Solution
- Route
- Intravenous; Intramuscular; Intra-Arterial
- Therapeutic class (ATC)
- Methotrexate L01BA01
- Class
- Human
- Record last updated
- June 17, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| METHOTREXATE (METHOTREXATE SODIUM) | 15 MG | 1.5 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- December 22, 2008: NOC 9959Supplement to an Abbreviated New Drug Submission (SANDS) · Addition of new strengths
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “metoject”. A notice may cover another product or only some lots: read it to see what it covers.
- Metoject (2015-03-17)April 1, 2015 · Drugs · Product safety · Type III
Other DINs named METOJECT
- DIN 02304767 · Cancelled Post Market
- DIN 02320029 · Cancelled Post Market
- DIN 02320037 · Cancelled Post Market
- DIN 02320053 · Cancelled Post Market